Pfizer, Inc. Press Releases

PFE 
$29.11
*  
0.51
1.78%
Get PFE Alerts
*Delayed - data as of Oct. 24, 2014  -  Find a broker to begin trading PFE now
Exchange: NYSE
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By
Pfizer Declares 26-Cent Fourth-Quarter 2014 Dividend
10/23/2014 4:05:00 PM - Business Wire
▲1.78 % Price Change since this news event. The Volume Ratio is 0.84.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Pfizer Wins SUTENT® Patent Case In Delaware District Court
10/23/2014 8:00:00 AM - Business Wire
▲2.50 % Price Change since this news event. The Volume Ratio is 0.92.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


ViiV Healthcare Expands Program to Reduce HIV Disparities in Southern U.S.
10/20/2014 9:00:00 AM - PR Newswire


FDA Approves Abuse Deterrent Labeling for EMBEDA® (morphine sulfate and naltrexone hydrochloride) Extended-Release (ER) Capsules CII
10/17/2014 4:38:00 PM - Business Wire
▲5.01 % Price Change since this news event. The Volume Ratio is 1.21.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Pfizer Announces FDA Acceptance Of Palbociclib New Drug Application With Priority Review
10/13/2014 8:00:00 AM - Business Wire
▲0.07 % Price Change since this news event. The Volume Ratio is 1.42.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Pfizer to Present New Data Evaluating Safety, Tolerability and Immunogenicity of its Investigational Staphylococcus aureus Vaccine Candidate at IDWeek 2014™
10/10/2014 8:00:00 AM - Business Wire
▲0.73 % Price Change since this news event. The Volume Ratio is 1.53.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Pfizer and Breast Cancer Leaders Join Together to Increase Understanding and Dispel Myths about Metastatic Breast Cancer
10/8/2014 8:30:00 AM - Business Wire


Pfizer To Present Safety And Immunogenicity Data From A Phase 2 Study Of Its Investigational Meningococcal Group B Vaccine, Bivalent rLP2086, Co-Administered With A Licensed Human Papillomavirus Vaccine
10/8/2014 8:00:00 AM - Business Wire


Portola Pharmaceuticals Announces Phase 3 ANNEXA(TM)-A Study of Andexanet Alfa and Eliquis (Apixaban) Met Primary and Secondary Endpoints With High Statistical Significance
10/1/2014 8:00:00 AM - GlobeNewswire


Pfizer And Kyowa Hakko Kirin To Collaborate On Immuno-Oncology Combination Study
9/29/2014 8:00:00 PM - Business Wire


Pfizer And Kyowa Hakko Kirin To Collaborate On Immuno-Oncology Combination Study
9/29/2014 8:00:00 PM - Business Wire


GlycoMimetics Announces a Delay in the Initiation of the Phase 3 Trial With Rivipansel
9/26/2014 9:01:00 AM - GlobeNewswire


Pain Therapeutics Expands Pipeline With FENROCK(TM), an Abuse-Deterrent Pain Patch
9/26/2014 7:30:00 AM - GlobeNewswire


Pfizer Completes Acquisition Of InnoPharma
9/25/2014 8:00:00 AM - Business Wire


Pfizer Invites Public to View and Listen to Webcast of October 28 Conference Call with Analysts
9/23/2014 10:00:00 AM - Business Wire


Kim Cattrall Encourages Women to Embrace Menopause with Style
9/23/2014 8:00:00 AM - Business Wire


Bristol-Myers Squibb and Pfizer Announce Charitable Donations of More Than $1 Million to Support Cardiovascular Education for Patients and Caregivers
9/22/2014 8:00:00 AM - Business Wire


Pfizer Foundation Provides $2 Million In Grants To Support ‘Last-Mile’ Vaccine Coverage In Africa
9/19/2014 8:00:00 AM - Business Wire


Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
9/3/2014 10:00:00 AM - Business Wire


Secondary Analysis of AMPLIFY-EXT Examining Predictors of Hospitalization Presented at ESC Congress: Eliquis (apixaban) Significantly Reduced the Risk of All-Cause Hospitalization Versus Placebo in Patients with Venous Thromboembolism (VTE)
8/30/2014 5:15:00 AM - Business Wire


InnoPharma Announces FDA Approval of Decitabine for Injection, a Generic Version of DACOGEN®
8/29/2014 10:13:00 AM - PR Newswire


Pfizer and Protalix BioTherapeutics Announce FDA Approval of Pediatric Indication for ELELYSO™ (taliglucerase alfa) for Injection, for Intravenous Use for the Treatment of Type 1 Gaucher Disease
8/28/2014 1:15:00 PM - Business Wire


Pfizer’s Investigational Vaccine Candidate for Clostridium difficile Receives U.S. Food and Drug Administration Fast Track Designation
8/28/2014 8:00:00 AM - Business Wire


Pfizer And Merck To Collaborate On Study Evaluating Novel Anti-Cancer Combination Regimen
8/26/2014 8:00:00 AM - Business Wire


Multimedia assets now available: ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection
8/25/2014 9:00:00 AM - PR Newswire